penses for EUR 2.5 million and 
the costs incurred for the Stock Option plan for 
EUR 1.0 million, offset by a net gain on the 
contribution in kind of the IP to the groups new 
Joint Venture Pantera for EUR 2.2 million (net of 
other investors interests). The reorganization 
expenses mostly relate to the discontinuation of 
the Dynamitron line of business in the US. This 
was 
a 
non-core 
business 
for 
IBA 
and 
Management decided to re-focus its efforts on 
developing its other sterilization devices.